ATE205403T1 - Zusammensetzungen welche aldosereductasehemmer und glycogen phosphorylase hemmer enthalten - Google Patents

Zusammensetzungen welche aldosereductasehemmer und glycogen phosphorylase hemmer enthalten

Info

Publication number
ATE205403T1
ATE205403T1 AT98949193T AT98949193T ATE205403T1 AT E205403 T1 ATE205403 T1 AT E205403T1 AT 98949193 T AT98949193 T AT 98949193T AT 98949193 T AT98949193 T AT 98949193T AT E205403 T1 ATE205403 T1 AT E205403T1
Authority
AT
Austria
Prior art keywords
inhibitors
compositions containing
aldose reductase
glycogen phosphorylase
containing aldose
Prior art date
Application number
AT98949193T
Other languages
English (en)
Inventor
Banavara Lakshman Mylari
Dennis Jay Hoover
Bernard Hulin
Judith Lee Treadway
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of ATE205403T1 publication Critical patent/ATE205403T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Superheterodyne Receivers (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Noise Elimination (AREA)
AT98949193T 1997-11-21 1998-11-02 Zusammensetzungen welche aldosereductasehemmer und glycogen phosphorylase hemmer enthalten ATE205403T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6636597P 1997-11-21 1997-11-21
PCT/IB1998/001752 WO1999026659A1 (en) 1997-11-21 1998-11-02 Combination of an aldose reductase inhibitor and a glycogen phosphorylase inhibitor

Publications (1)

Publication Number Publication Date
ATE205403T1 true ATE205403T1 (de) 2001-09-15

Family

ID=22069038

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98949193T ATE205403T1 (de) 1997-11-21 1998-11-02 Zusammensetzungen welche aldosereductasehemmer und glycogen phosphorylase hemmer enthalten

Country Status (38)

Country Link
EP (1) EP1032424B9 (de)
JP (1) JP2002504478A (de)
KR (2) KR20010032304A (de)
CN (1) CN1279617A (de)
AP (1) AP911A (de)
AR (1) AR016423A1 (de)
AT (1) ATE205403T1 (de)
AU (1) AU733304B2 (de)
BG (1) BG104435A (de)
BR (1) BR9814698A (de)
CA (1) CA2310069A1 (de)
DE (1) DE69801680T2 (de)
DK (1) DK1032424T3 (de)
DZ (1) DZ2656A1 (de)
EA (1) EA002365B1 (de)
ES (1) ES2161548T3 (de)
GR (1) GR3037071T3 (de)
GT (1) GT199800166A (de)
HR (1) HRP20000327A2 (de)
HU (1) HUP0100272A3 (de)
ID (1) ID24524A (de)
IL (1) IL135713A0 (de)
IS (1) IS5453A (de)
MA (1) MA26568A1 (de)
NO (1) NO20002164L (de)
OA (1) OA11379A (de)
PA (1) PA8462301A1 (de)
PE (1) PE135399A1 (de)
PL (1) PL340643A1 (de)
PT (1) PT1032424E (de)
SK (1) SK7222000A3 (de)
TN (1) TNSN98211A1 (de)
TR (1) TR200001451T2 (de)
UA (1) UA57811C2 (de)
UY (1) UY25258A1 (de)
WO (1) WO1999026659A1 (de)
YU (1) YU30700A (de)
ZA (1) ZA9810636B (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002536410A (ja) * 1999-02-12 2002-10-29 ノボ ノルディスク アクティーゼルスカブ 肥満の治療又は予防もしくは食欲の調節を目的とした薬学的組成物の製造におけるピロリジン誘導体の使用
EP1743655B1 (de) 2000-01-21 2014-06-25 Novartis AG Zusammensetzungen bestehend aus dipeptidylpeptidase-iv inhibitoren und antidiabetica
CO5271699A1 (es) 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
US6570013B2 (en) 2000-02-16 2003-05-27 Pfizer Inc Salts of zopolrestat
US6395767B2 (en) * 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
IL144507A0 (en) * 2000-07-31 2002-05-23 Pfizer Prod Inc Use of glycogen phosphorylase inhibitors to inhibit tumor growth
WO2002098429A1 (en) * 2001-06-07 2002-12-12 Pfizer Products Inc. Ethanolamine, diethanolamine or triethanolamine salt of zopolrestat
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
CA2392486A1 (en) 2002-07-05 2002-12-08 Duchesnay Inc. Pharmaceutical dosage form bearing pregnancy-friendly indicia
US7098235B2 (en) 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
SG134333A1 (en) 2003-11-12 2007-08-29 Phenomix Corp Heterocyclic boronic acid compounds
US7767828B2 (en) 2003-11-12 2010-08-03 Phenomix Corporation Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7317109B2 (en) 2003-11-12 2008-01-08 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7576121B2 (en) 2003-11-12 2009-08-18 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
EP1778220A1 (de) 2004-07-12 2007-05-02 Phenomix Corporation Eingezwängte cyano-verbindungen
US7223786B2 (en) 2004-11-15 2007-05-29 Bristol-Myers Squibb Company 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors
US7226942B2 (en) 2004-11-15 2007-06-05 Bristol-Myers Squibb Company 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006053274A2 (en) 2004-11-15 2006-05-18 Bristol-Myers Squibb Company 2-amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006055463A2 (en) 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US20060235028A1 (en) 2005-04-14 2006-10-19 Li James J Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
US7825139B2 (en) 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
PT1931350E (pt) 2005-09-14 2014-02-12 Takeda Pharmaceutical Administração de inibidores de dipeptidil peptidase
EP2046753A2 (de) 2006-07-06 2009-04-15 Brystol-Myers Squibb Company Pyridon/hydroxypyridin-11-beta-hydroxysteroid-dehydrogenase-hemmer vom typ i
US7727978B2 (en) 2006-08-24 2010-06-01 Bristol-Myers Squibb Company Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
EP2142551B1 (de) 2007-04-17 2015-10-14 Bristol-Myers Squibb Company KONDENSIERTE HETEROCYCLISCHE Verbindungen als Hemmer der BETA-HYDROXYSTEROID-DEHYDROGENASE -TYP I
ES2388315T3 (es) 2007-05-04 2012-10-11 Bristol-Myers Squibb Company Agonistas [6,5]-bicíclicos de receptores GPR119 acoplados a la proteína G
US7910583B2 (en) 2007-05-04 2011-03-22 Bristol-Myers Squibb Company [6,6] and [6,7]-bicyclic GPR119 G protein-coupled receptor agonists
EA016595B1 (ru) 2007-07-17 2012-06-29 Бристол-Маерс Сквибб Компани Способ модулирования рецептора gpr119, сопряженного с g-белком, и используемые при этом соединения
TW201006821A (en) 2008-07-16 2010-02-16 Bristol Myers Squibb Co Pyridone and pyridazone analogues as GPR119 modulators
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
PL2531501T3 (pl) 2010-02-03 2014-05-30 Takeda Pharmaceuticals Co Inhibitory kinazy 1 regulującej sygnał apoptotyczny
SG184168A1 (en) 2010-04-08 2012-10-30 Bristol Myers Squibb Co Pyrimidinylpiperidinyloxypyridinone analogues as gpr119 modulators
CN102971313A (zh) 2010-04-14 2013-03-13 百时美施贵宝公司 新颖的葡糖激酶激活剂及其使用方法
US8729084B2 (en) 2010-05-06 2014-05-20 Bristol-Myers Squibb Company Benzofuranyl analogues as GPR119 modulators
US8940716B2 (en) 2010-05-06 2015-01-27 Bristol-Myers Squibb Company Bicyclic heteroaryl compounds as GPR119 modulators
ES2555927T3 (es) 2011-01-20 2016-01-11 Bionevia Pharmaceuticals Inc. Composiciones de liberación modificada de epalrestat o un derivado del mismo y métodos para el uso de las mismas
WO2013173198A1 (en) 2012-05-16 2013-11-21 Bristol-Myers Squibb Company Pyrimidinylpiperidinyloxypyridone analogues as gpr119 modulators
WO2015061272A1 (en) 2013-10-22 2015-04-30 Bristol-Myers Squibb Company Isotopically labeled triazolopyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors
JP7072557B2 (ja) 2016-07-22 2022-05-20 ブリストル－マイヤーズ スクイブ カンパニー グルコキナーゼ活性化剤およびその使用方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4825448A (en) * 1986-08-07 1989-04-25 International Mobile Machines Corporation Subscriber unit for wireless digital telephone system
DE3889326D1 (de) * 1988-05-27 1994-06-01 Itt Ind Gmbh Deutsche Korrekturschaltung für ein digitales Quadratur-Signalpaar.
US5391551A (en) * 1993-05-10 1995-02-21 Pfizer Inc. Method of lowering blood lipid levels
FI974437A7 (fi) * 1995-06-06 1997-12-05 Pfizer Substituoituja N-(indoli-2-karbonyyli)amideja ja johdannaisia glykogee nifosforylaasi-inhibiittoreina
DE69523182T2 (de) * 1995-06-06 2002-02-07 Pfizer Substituierte n-(indol-2-carbonyl)-glycinamide und derivate als glycogen phosphorylase inhibitoren

Also Published As

Publication number Publication date
WO1999026659A1 (en) 1999-06-03
YU30700A (sh) 2002-12-10
PT1032424E (pt) 2001-12-28
ID24524A (id) 2000-07-20
MA26568A1 (fr) 2004-12-20
BG104435A (bg) 2001-01-31
EP1032424B9 (de) 2004-10-06
HUP0100272A2 (hu) 2001-06-28
EP1032424A1 (de) 2000-09-06
PL340643A1 (en) 2001-02-12
EP1032424B1 (de) 2001-09-12
OA11379A (en) 2004-01-28
NO20002164L (no) 2000-07-19
NO20002164D0 (no) 2000-04-27
AU9555898A (en) 1999-06-15
TNSN98211A1 (fr) 2005-03-15
GR3037071T3 (en) 2002-01-31
PE135399A1 (es) 2000-01-15
IL135713A0 (en) 2001-05-20
KR20010032304A (ko) 2001-04-16
CA2310069A1 (en) 1999-06-03
CN1279617A (zh) 2001-01-10
AU733304B2 (en) 2001-05-10
AP9801401A0 (en) 1998-12-31
HUP0100272A3 (en) 2002-11-28
DE69801680T2 (de) 2002-02-07
KR20010032300A (ko) 2001-04-16
PA8462301A1 (es) 2000-05-24
DZ2656A1 (fr) 2003-03-22
DE69801680D1 (de) 2001-10-18
SK7222000A3 (en) 2001-09-11
IS5453A (is) 2000-04-14
AP911A (en) 2000-12-07
AR016423A1 (es) 2001-07-04
ES2161548T3 (es) 2001-12-01
DK1032424T3 (da) 2001-11-19
EA002365B1 (ru) 2002-04-25
KR100661214B1 (ko) 2006-12-26
TR200001451T2 (tr) 2002-06-21
JP2002504478A (ja) 2002-02-12
EA200000433A1 (ru) 2000-12-25
GT199800166A (es) 2000-04-19
HRP20000327A2 (en) 2001-02-28
UY25258A1 (es) 2000-12-29
UA57811C2 (uk) 2003-07-15
ZA9810636B (en) 2000-05-22
BR9814698A (pt) 2000-10-03

Similar Documents

Publication Publication Date Title
ATE205403T1 (de) Zusammensetzungen welche aldosereductasehemmer und glycogen phosphorylase hemmer enthalten
ATE251892T1 (de) Schäumende öl-zusammensetzung und ihre verwendung
DE69637691D1 (de) Azeotropähnliche zusammensetzungen und ihre verwendung
DE69638056D1 (de) Azeotropähnliche zusammensetzungen und ihre verwendung
HUP0103575A3 (en) Inhibitors of caspases, pharmaceutical compositions comprising thereof and their use
DE69932552D1 (de) Pulver-Zusammensetzung und kosmetische Zusammensetzung enthaltend dieselbe
DE60014599D1 (de) Zusammensetzungen aus difluormethan, pentafluorethan, 1,1,1,2-tetrafluorethan und kohlenwasserstoffen
DE59913617D1 (de) Indolderivate und deren Verwendung als Inhibitoren der Phosphodiesterase 4.
EP1188781A4 (de) Schlagzäh-modifizierer und diese modifizierer enthaltende polyesterzusammensetzung
ATE277895T1 (de) 4-brom or 4-iod-phenylamino- benzhydroxamsäurederivate und ihre anwendung als mek-inhibitoren
DE69823804D1 (de) Azeotrope methoxyperfluorpropanzusammensetzungen und deren verwendung
NO20011950D0 (no) Farmasöytisk sammensetning inneholdende poly(ADP- ribose)glykohydrolaseinhibitorer og anvendelser av de samme
DE69915066D1 (de) Biozide zusammensetzung und deren verwendung
ATE186447T1 (de) Zusammensetzung und verwendung
LT99141A (lt) Tizoksanido ir nitazoksanido farmacinės kompozicijos
HUP0102646A3 (en) Phthalazine derivatives phosphodiesterase 4 inhibitors and pharmaceutical compositions containing the same
DE69800435D1 (de) Feste kosmetische Zusammensetzung sowie ihre Verwendungen
ATE274024T1 (de) Sauerstoffabsorbierende zusammensetzung und ihre anwendungsmethode
DE69900414D1 (de) Verzögerungssysteme und verwendung in ölbohrlochzementierungen
ID26297A (id) Celana jenis celana pendek sekali pakai dan proses pembuatannya
DE69828864D1 (de) Pigmentzusammensetzung und damit hergestellte wässrige Pigmentdispersion
FI962327A0 (fi) Kaasumaisten päästöjen vähentäminen hakesiilosta
DE69620914D1 (de) Perfluoralkoxycycloalkancarbonylfluorid-zusammensetzungen und ihre verwendung
FR2783711B1 (fr) Compositions cosmetiques photoprotectrices et utilisations
DE69915591D1 (de) Zusammensetzungen von 1,1,1,3,3-pentafluorpropan und trans-1,2-dichlorethylen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee